Patent application number | Description | Published |
20080306142 | Isolation, purification and synthesis of procyanidin B2 and uses thereof - Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus | 12-11-2008 |
20080306143 | Cathechins for the Treatment of Fibrillogenesis in Alzheimer's Disease, Parkinson's Disease, Systemic AA Amyloidosis, and Other Amyloid Disorders - A method of treating an amyloid disease, or a disease characterized by alpha-synuclein or NAC fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins or green tea extract. A pharmaceutical composition comprising a therapeutically effective amount of a catechin and a pharmaceutically acceptable excipient. The therapeutic amount of the catechin or green tea extract is selected for efficacy in treating amyloid, alpha-synuclein or NAC fibrillogenesis in a mammalian subject. | 12-11-2008 |
20080306286 | Isolation, Purification and Synthesis of Procyanidin B2 and Uses Thereof - Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus | 12-11-2008 |
20090060838 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES - Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and diagnosis of amyloid and synuclein diseases. | 03-05-2009 |
20090111863 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies - Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment. | 04-30-2009 |
20090123575 | Blended Compositions for Treatment of Alzheimer's Disease and Other Amyloidoses - Methods for treating amyloid disease in a patient wherein the method comprises administration of a therapeutically effective amount of a composition comprising | 05-14-2009 |
20100331380 | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies - Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment. | 12-30-2010 |
20110097428 | Blended Compositions for Treatment of Alzheimer's Disease and Other Amyloidoses - Methods for treating amyloid disease in a patient wherein the method comprises administration of a therapeutically effective amount of a composition comprising | 04-28-2011 |
20110104055 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES - Compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and detection of amyloid and synuclein. | 05-05-2011 |